ERBB2 and breast carcinoma: Furthermore, the study demonstrated increased DC, T cell, and NK cell activation and repolarization of M2 macrophages.[112] After promising in vivo data, the ADC XMT‐2056 binding HER2 entered a clinical phase I trial (NCT05514717).[113] A CD11b‐STINGa‐ADC demonstrated STING activation in tumor cells and complete tumor regression in an ovarian and breast cancer xenograft mouse model.